Goldman Sachs maintains Buy on BioMarin shares By Investing.com

Published on 14 Jan 2025 on Investing.com

On Tuesday, Goldman Sachs reiterated its Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN),...

Read the rest of the article

Start tracking your investments with Statfolio

The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adul...

Zacks · via Yahoo Finance 1 Feb 2025

Vertex Pharmaceuticals Incorporated VRTX announced that the FDA has approved its oral, non-opioid...

Zacks · via Yahoo Finance 31 Jan 2025

BioMarin Pharmaceutical (BMRN) San Rafael, CA-based BioMarin Pharmaceutical Inc. focuses on the...

Zacks · via Yahoo Finance 31 Jan 2025

The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced...

Zacks · via Yahoo Finance 28 Jan 2025

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with t...

Zacks · via Yahoo Finance 28 Jan 2025

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we ar...

Insider Monkey · via Yahoo Finance 28 Jan 2025

We recently compiled a list of the Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks. ...

Insider Monkey · via Yahoo Finance 23 Jan 2025

Chicago, IL – January 23, 2025 – Stocks in this week’s article are — BioMarin Pharmaceutical Inc....

Zacks · via Yahoo Finance 23 Jan 2025

JNJ's Zacks Rank & Stocks to Consider J&J currently carries a Zacks Rank #3 (Hold). Some...

Zacks · via Yahoo Finance 23 Jan 2025

Passive investing in an index fund is a good way to ensure your own returns roughly match the...

Simply Wall St. · via Yahoo Finance 21 Jan 2025